– USA, NH – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the appointment of Stacey Stevens to its Board of Directors as President and CEO, effective March 1, 2022, to succeed Michael Klein who will continue to serve as Chairman of the Board of Directors.
“On behalf of the entire Board of Directors, I would like to congratulate Ms. Stevens on this appointment. It has been a privilege to work closely with her for the past three years, as she brings a relentless focus on leading change and a proven track record of driving growth and innovation. I look forward to continued interaction in her new capacity as CEO,” said Michael Klein, Chairman and current CEO.
He added: “We are currently at an important inflection point, with the recent launch of several first-in-kind technologies and the Company’s increasing focus on enterprise sales on the Detection side of the business, and with the expansion of Xoft in emerging applications, such as the treatment of brain tumors, on the Therapy side of the business. I am confident that with Ms. Stevens at the helm, iCAD and its technologies will continue to transform the landscape of cancer detection and therapy and accelerate the value we bring to all of our stakeholders.”
About Stacey Stevens
An accomplished executive with more than 20 years of marketing, strategy, and sales experience, Ms. Stevens has served as iCAD’s President since 2019. Before that, she served as EVP and Chief Strategy and Commercial Officer from 2017-2019. Ms. Stevens joined iCAD in 2006 as SVP of Marketing and Strategy. Before her tenure at iCAD, she held numerous commercial leadership positions across multiple business units at Philips Healthcare.
“I am honored to have the opportunity to lead the company at this exciting time in our growth,” commented Stacey Stevens. “iCAD’s technologies offer clinical performance superiority, workflow improvements, and a broad healthcare economic value proposition for both clinicians and patients. We are enhancing patient care and optimizing outcomes, which ultimately translates to improving, extending, and saving lives. I look forward to working with our talented and passionate team to advance the Company as we continue to evolve our business and technology, drive sustained market leadership, and create additional significant shareholder value.”
Ms. Stevens earned a Bachelor of Arts Degree in Political Science from the University of New Hampshire, and an MBA from Boston University’s Questrom School of Business. Ms. Stevens was named one of CEO Today’s “Businesswomen of the Year” in 2021.
About iCAD, Inc.
Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions.
For more information: https://www.icadmed.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
